Mp29-03 multi-Institutional Analysis of Metastasis Directed Therapy With or Without Androgen Deprivation Therapy in Oligometastatic Castration Sensitive Prostate Cancer

Deek, Matthew P.; Sutera, Phillip; Jing, Yuezhou; Pryor, David B.; Day, Heather; Huynh, Mai Anh; Koontz, Bridget F.; Armstrong, Andrew J.; Debruycker, Ellen; Dirix, Piet; Mercier, Carole; Ost, Piet; Song, Danny Y.; Conde-Moreno, Antonio J.; Berenguer, M.A.; Stish, Bradley J.; Buroker, Justine; Bosetti, D.; Bruce, Melissa; Berlín, Alejandro; Ramotar, Matthew; Kroeze, S.G.C.; Corcoran, Niall M.; Nicholas, Howard; Trock, Bruce J.; Gillessen, Silke; Tran, Phuoc T.; Sweeney, Christopher J.

doi:10.1097/ju.0000000000003257.03

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deek et al recently presented the results of a multi-institutional cohort study involving 263 patients with oligometastatic prostate cancer who underwent MDT at the 2023 AUA meeting [ 67 ]. In this retrospective analysis, the authors observed that the addition of ADT to MDT was associated with an improved time to biochemical progression (HR 0.23; 95% CI 0.16–0.33, p < 0.001).…”

Section: Trials Ongoing and Future Directionsmentioning

confidence: 99%

Node Oligorecurrence in Prostate Cancer: A Challenge

Zapatero,

Conde Moreno,

Barrado Los Arcos

et al. 2023

Cancers

View full text Add to dashboard Cite

Within the oligometastatic state, oligorecurrent lymph node disease in prostate cancer represents an interesting clinical entity characterized by a relatively indolent biology that makes it unique: it can be treated radically, and its treatment is usually associated with a long period of control and excellent survival. Additionally, it is an emergent situation that we are facing more frequently mainly due to (a) the incorporation into clinical practice of the PSMA-PET that provides strikingly increased superior images in comparison to conventional imaging, with higher sensitivity and specificity; (b) the higher detection rates of bone and node disease with extremely low levels of PSA; and (c) the availability of high-precision technology in radiotherapy treatments with the incorporation of stereotaxic body radiotherapy (SBRT) or stereotaxic ablative radiotherapy (SABR) technology that allows the safe administration of high doses of radiation in a very limited number of fractions with low toxicity and excellent tolerance. This approach of new image-guided patient management is compelling for doctors and patients since it can potentially contribute to improving the clinical outcome. In this work, we discuss the available evidence, areas of debate, and potential future directions concerning the utilization of new imaging-guided SBRT for the treatment of nodal recurrence in prostate cancer.

show abstract

Section: Trials Ongoing and Future Directionsmentioning

confidence: 99%